Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 booster study of VLPCOV-02 SARS-CoV-2 saRNA vaccine in healthy adults
jRCT2051230005Phase 2Completed
- Sponsor
- VLP Therapeutics Japan
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of VLPCOV-02 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by VLP Therapeutics Japan. Primary endpoints: Incidence and severity of solicited local adverse events through 7 days after study drug inoculation, Incidence and severity of solicited systemic adverse events through 7 days after study drug inoculation and 5 more. Started Apr 2023; status: completed.
02
Drugs
VLPCOV-02
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051230005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230005.